Global Melanoma Drugs Market Size 2024, Forecast To 2033
6 Mar, 2024
The melanoma drugs market size has experienced rapid growth, surging from $8.27 billion in 2023 to $9.27 billion in 2024, with a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to clinical research advances, increased incidence rates, changing treatment landscape, improved diagnosis techniques, and regulatory approvals. Looking ahead, the market is anticipated to witness rapid growth, reaching $13.98 billion in 2028 with a CAGR of 10.8%. The forecast period's growth can be attributed to immunotherapy advancements, biomarker research, the global aging population, market expansion in emerging economies, and collaborative research initiatives. Major trends in the forecast period include innovations in adjuvant therapies, expanded use of checkpoint inhibitors, patient stratification strategies, integration of real-world evidence, and global collaborations in clinical trials.
Global Melanoma Drugs Market Key Driver
The increase in the incidence of melanoma in males is expected to propel the growth of the melanoma drug market over the coming years. Melanoma is a type of skin cancer developed in the cells (melanocytes) that regulate the pigment in the skin. Melanoma drugs are medications used to treat melanoma, and these drugs aim to target and inhibit the growth and spread of melanoma cells in the body. Hence the increasing incidence of melanoma will increase the demand for melanoma drugs market. For instance, in 2023, according to the report published by the American Cancer Society, Inc, a US-based nationwide voluntary health organization dedicated to eliminating cancer, new male individuals suffering from melanoma in the United States increased to 58,120 in 2023 from 57,180 in 2022. Therefore, an increase in incidences of melanoma in males is driving the growth of the melanoma drug market.
Get A Free Sample Of The Global Melanoma Drugs Market ReportGlobal Melanoma Drugs Market Segments
The melanoma drugs market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Targeted Therapy
2) By Disease Type: Superficial Spreading Melanoma, Lentigo Maligna, Acral Lentiginous Melanoma, Nodular Melanoma
3) By Application: Hospitals, Outpatient Oncologist Clinics, Other Applications
By Geography:The regions covered in the melanoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the melanoma drugs market in 2023. The regions covered in the melanoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Melanoma Drugs Industry Players
Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche A, GlaxoSmithKline plc, Janssen Biotech Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Genentech Inc., Merck & Co. Inc., Bayer AG, Bausch Health Companies Inc., Cipla Limited, Vical Incorporated, Aduro Biotech Inc., OSE Immunotherapeutics, Daiichi Sankyo Company Limited, Gilead Sciences, Seagen Inc., Incyte Corporation, Kyowa Kirin Co. Ltd., Almirall S.A., MacroGenics Inc., Prometheus Biosciences Inc., Fortress Biotech Inc., OncoSec Medical Incorporated, Regeneron Pharmaceuticals Inc., Iovance Biotherapeutics
Get The Full Global Melanoma Drugs Market Report
Melanoma Drugs Market Overview
Melanoma drug refers to a drug used for the medication of skin cancer that develops in the cells that produce melanin, the pigment responsible for the color of the skin, hair, and eyes. Melanoma drugs are used to treat melanoma that aims to target and inhibit the growth and spread of melanoma cells in the body.
Melanoma Drugs Global Market Report 2023 provides data on the global melanoma drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The melanoma drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.